BCL2 and acute myeloid leukemia: While the Bcl-2 inhibitor Venetoclax is currently being tested as a single agent in clinical trials (10), recent studies have also shown that Venetoclax in combination with DNMT inhibitor Azacytidine has more striking effects in targeting LSCs in AML patients (11–13).